Taysha Gene Therapies (TSHA) Treasury Shares (2020 - 2026)

Taysha Gene Therapies has disclosed Treasury Shares across 7 years of filings, most recently posting $10.9 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $10.9 million, up 74.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (up 74.29% YoY), and the FY2025 annual result was $6.3 million, up 38.73% from the prior year.
• Treasury Shares came in at $10.9 million for Q1 2026 at Taysha Gene Therapies, up from $6.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $10.9 million in Q1 2026 to a low of $69344.0 in Q1 2023.
• The 5-year median for Treasury Shares is $1.9 million (2022), against an average of $3.4 million.
• Across the five-year window, Treasury Shares tumbled 96.32% in 2023 and surged 1112.97% in 2024, its largest moves.
• Taysha Gene Therapies' Treasury Shares stood at $1.3 million in 2022, then slumped by 70.18% to $375044.0 in 2023, then soared by 1112.97% to $4.5 million in 2024, then soared by 38.73% to $6.3 million in 2025, then soared by 72.37% to $10.9 million in 2026.
• The last three Treasury Shares figures came in at $10.9 million (Q1 2026), $6.3 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.